Treating headache comprising administering an antibody to calcitonin gene-related peptide
AssigneeTeva Pharmaceuticals International GmbH
InventorsMarcelo Bigal, Sarah Walter, Henry Stern, Michael Chang
Life of this patent
Estimating the term…
Abstract
The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms and/or headaches (e.g., migraine, cluster headache, and tension headache) by administering an anti-CGRP antagonist antibody. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
Claims43
A method of treating or reducing incidence of headache associated with the administration of a substance or its withdrawal in a subject, comprising administering to the subject a monthly dose of a monoclonal antibody that inhibits the calcitonin gene-related peptide (CGRP) pathway, wherein the amount administered monthly is between 100-900 mg, wherein the monoclonal antibody comprises a CDR H1 as set forth in SEQ ID NO:3;
- a CDR H2 as set forth in SEQ ID NO:4;
- a CDR H3 as set forth in SEQ ID NO:5;
- a CDR L1 as set forth in SEQ ID NO:6;
- a CDR L2 as set forth in SEQ ID NO:7;
- and a CDR L3 as set forth in SEQ ID NO:8, and wherein the substance is an anti-headache medication.
A method of treating or reducing incidence of headache associated with the administration of a substance or its withdrawal in a subject, comprising administering to the subject a monthly dose of a monoclonal antibody that inhibits the calcitonin gene-related peptide (CGRP) pathway, wherein the monoclonal antibody comprises a CDR H1 as set forth in SEQ ID NO:3;
- a CDR H2 as set forth in SEQ ID NO:4;
- a CDR H3 as set forth in SEQ ID NO:5;
- a CDR L1 as set forth in SEQ ID NO:6;
- a CDR L2 as set forth in SEQ ID NO:7;
- and a CDR L3 as set forth in SEQ ID NO:8, wherein the amount administered monthly is about 225 mg, wherein the monoclonal antibody is formulated at a concentration of at least 150 mg/mL, and wherein the substance is an anti-headache medication.
A method of treating or reducing incidence of headache associated with the administration of a substance or its withdrawal in a subject, comprising administering to the subject a monthly dose of a monoclonal antibody that inhibits the calcitonin gene-related peptide (CGRP) pathway, wherein the monoclonal antibody comprises a CDR H1 as set forth in SEQ ID NO:3;
- a CDR H2 as set forth in SEQ ID NO:4;
- a CDR H3 as set forth in SEQ ID NO:5;
- a CDR L1 as set forth in SEQ ID NO:6;
- a CDR L2 as set forth in SEQ ID NO:7;
- and a CDR L3 as set forth in SEQ ID NO:8, wherein the amount administered monthly is about 675 mg, wherein the monoclonal antibody is formulated at a concentration of at least 150 mg/mL, and wherein the substance is an anti-headache medication.
Dependencies are inferred from the claim text.